Guardant360®
Home » Guardant360®

Searching for
guideline-recommended
genomic information?

Get results fast.

Guide treatment decisions in 7 days*
with Liquid Biopsy.

*Upon sample receipt in the laboratory

High Concordance with Tissue1

concordanse

for targetable alterations*
before first-line therapy (n=81)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF

High Concordance with Tissue1

concordanse

for targetable alterations*
before first-line therapy (n=81)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF

Tissue has limitations beyond your control

Tissue has limitations beyond your control

Treatment delays


Results may be unpredictable
and incomplete

Patient burden


Repeated tissue biopsies
may expose patients to
potential adverse events

Finite resource


Tissue exhausted by histopathology stains and PD-L1 testing

Practice/staff burden


Coordination involving
multiple care team members

Relying solely on tissue leads to undergenotyping

~1 in 2 NSCLC patients are unable to get complete genomic results from tissue1

EGFR
ALK
ROSI
BRAF
MET
RET
ERBB2 (HER2)
NTRK

When to use Guardant360®

When to use Guardant360®

Before 1st Line Treatment

Get ahead of the challenges of tissue testing in
advanced NSCLC by utilizing Guardant360 to guide 1L
treatment decisions

At Disease Progression

Get genomic information on over 70+ genes relevant across
multiple solid tumors including MSI-High to help find pan cancer
therapies and clinical trials.

Published Data

Prospective study of 323 NSCLC patients found
Guardant360 improved alteration detection1

Published Data

Prospective study of 323 NSCLC patients found
Guardant360 improved alteration detection1

44_patients_agree_tissue_testing

were unable to get genomic results
from tissue biopsy

1.7x_as_many_patients

had targetable alterations* detected
by Guardant360® and tissue testing (n=82) versus tissue testing alone (n=47)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF.

853.7_percentage

had an objective tumor response or stable disease based on RECIST

44_patients_agree_tissue_testing

were unable to get genomic results
from tissue biopsy

1.7x_as_many_patients

had targetable alterations* detected
by Guardant360® and tissue testing (n=82) versus tissue testing alone (n=47)
*EGFR, ALK, MET, BRCA1, ROS1, RET, ERBB2, or BRAF.

853.7_percentage

had an objective tumor response or stable disease based on RECIST

NSCLC comprehensive results in 7 days from sample receipt at the laboratory

Test

with Guardant360® when patient is diagnosed with advanced NSCLC

Get results in 7 days

from sample receipt
at the laboratory to guide treatment decisions

Take action

with first-line
treatment

Findings from NILE Study

Guardant360 Assay Specifications Sheet

Findings from PENN2 Study

0
+
Clinical Samples Reported
0
+
Biopharma Partners
0
+
Ordering Oncologists
0
+
Peer-reviewed publications

Reference:
1. Aggarwal C, Thompson JC, Black TA, et al. Clinical implications of plasma-based genotyping with the delivery of personalized therapy in metastatic non-small cell lung cancer. JAMA Oncol. 2019;5(2):173-180.
MKTAMEA112020_015

NSCLC comprehensive results in 7 days from sample receipt at the laboratory

Test

with Guardant360® when patient is diagnosed with advanced NSCLC

Get results in 7 days

from sample receipt at the laboratory to guide treatment decisions

Take action

with first-line treatment

Open chat
Message us